JP2014531455A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531455A5
JP2014531455A5 JP2014532040A JP2014532040A JP2014531455A5 JP 2014531455 A5 JP2014531455 A5 JP 2014531455A5 JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014531455 A5 JP2014531455 A5 JP 2014531455A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutical composition
memory
peptide
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014532040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531455A (ja
JP6110861B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056728 external-priority patent/WO2013044147A1/en
Publication of JP2014531455A publication Critical patent/JP2014531455A/ja
Publication of JP2014531455A5 publication Critical patent/JP2014531455A5/ja
Application granted granted Critical
Publication of JP6110861B2 publication Critical patent/JP6110861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014532040A 2011-09-23 2012-09-21 ワクチン療法 Active JP6110861B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (3)

Publication Number Publication Date
JP2014531455A JP2014531455A (ja) 2014-11-27
JP2014531455A5 true JP2014531455A5 (cg-RX-API-DMAC7.html) 2015-11-12
JP6110861B2 JP6110861B2 (ja) 2017-04-05

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014532040A Active JP6110861B2 (ja) 2011-09-23 2012-09-21 ワクチン療法

Country Status (23)

Country Link
US (2) US20140314837A1 (cg-RX-API-DMAC7.html)
EP (1) EP2758071B1 (cg-RX-API-DMAC7.html)
JP (1) JP6110861B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160099732A (cg-RX-API-DMAC7.html)
CN (2) CN104039346A (cg-RX-API-DMAC7.html)
AU (1) AU2012312126B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014006871A2 (cg-RX-API-DMAC7.html)
CA (1) CA2811188C (cg-RX-API-DMAC7.html)
DK (1) DK2758071T3 (cg-RX-API-DMAC7.html)
EA (1) EA032494B1 (cg-RX-API-DMAC7.html)
ES (1) ES2712951T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041277T2 (cg-RX-API-DMAC7.html)
IL (1) IL231564A0 (cg-RX-API-DMAC7.html)
MX (1) MX350928B (cg-RX-API-DMAC7.html)
MY (1) MY169574A (cg-RX-API-DMAC7.html)
PH (1) PH12014500657A1 (cg-RX-API-DMAC7.html)
PL (1) PL2758071T3 (cg-RX-API-DMAC7.html)
PT (1) PT2758071T (cg-RX-API-DMAC7.html)
SG (1) SG11201400795UA (cg-RX-API-DMAC7.html)
SI (1) SI2758071T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901846T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013044147A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402071B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽,抗Tau抗体,及其使用方法
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
TW202333768A (zh) 2017-10-25 2023-09-01 美商健生醫藥公司 Tau胜肽之組成物及其用途
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202108312PA (en) 2019-02-08 2021-08-30 Ac Immune Sa Method of safe administration of phosphorylated tau peptide vaccine
CN113853214A (zh) * 2019-05-21 2021-12-28 Ac免疫有限公司 抗Aβ疫苗治疗
WO2024156912A1 (en) 2023-01-26 2024-08-02 Ac Immune Sa Anti-abeta vaccine therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009831A1 (en) 1997-08-28 1999-03-04 Ajay North America Methods and compositions for protecting plants and crops
KR20050101537A (ko) 2002-12-24 2005-10-24 뉴로켐 (인터내셔널) 리미티드 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 a-베타에 대한 항체를 생성하기 위한 능동 면역화
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
SI2336147T1 (sl) * 2003-12-17 2014-08-29 Janssen Alzheimer Immunotherapy Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih
AU2005290250A1 (en) * 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
CA2633399C (en) * 2005-12-12 2016-01-26 Ac Immune S.A. Therapeutic vaccine
CA2690434C (en) * 2007-06-12 2018-05-22 Ac Immune S.A. Monoclonal anti beta amyloid antibody
MX2011009654A (es) * 2009-03-18 2011-10-12 Ac Immune Sa Metodo para uso terapeutico.
EP2632434B1 (en) * 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Similar Documents

Publication Publication Date Title
Godyń et al. Therapeutic strategies for Alzheimer’s disease in clinical trials
JP5249043B2 (ja) 治療ワクチン
MY183989A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
Berk et al. Successes and failures for drugs in late-stage development for Alzheimer’s disease
Specchio et al. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis
JP2017153480A (ja) 治療的特性を有するβ1〜42特異的モノクローナル抗体
JP2012522754A5 (cg-RX-API-DMAC7.html)
RU2007145052A (ru) Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера
WO2006069081A2 (en) USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
JP2012520852A5 (cg-RX-API-DMAC7.html)
JP6110861B2 (ja) ワクチン療法
JP2022549654A (ja) Ranタンパク質疾患のためのワクチン治療
US20160355581A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
EP1469882B1 (en) Treatment of nervous system diseases with goat serum
Panwar et al. Emerging Novel therapeutic approaches for the treatment of Alzheimer’s disease
JP2015521636A (ja) in−vivoで神経変性疾患(特にアルツハイマー病)に活性なリポソーム
AU2003202093A1 (en) Treatment of MS with goat serum
JP2025506472A5 (cg-RX-API-DMAC7.html)
TW201617363A (zh) 含呼吸道融合病毒系19融合蛋白的仿病毒顆粒及其用途
WO2011090065A1 (ja) ペプチドワクチン
Kummer et al. Zolpidem misuse in two women with no psychiatric history: a crucial role of pleasant visual hallucinations
Armentia et al. 3 Postmarketing Study for Assessment of Tolerability of a Grass Allergen Immunotherapy Tablet (GRAZAX) in Patients With Rhinitis or Rhinoconjunctivitis
Hoglund et al. P4-386 The effect of simvastatin treatmnt the processing of the amyloid precursor protein in patients with Alzheimer's disease
TH2001005860A (th) วัคซีนทางการบำบัดชนิดต้าน a-เบตา
RS54074B1 (sr) Metode i kompozicije koje sadrže supramolekulske konstrukte